EGFR and esophageal squamous cell carcinoma: Conversely, high-score ESCC cells demonstrated significant resistance to EGFR inhibitors (e.g., Gefitinib) and BTK inhibitors (e.g., Ibrutinib), potentially mediated through compensatory EGFR pathway activation or drug efflux pump upregulation.